Zurich (awp) – Novartis has obtained marketing authorization from the European Commission for its Tabrecta (capmatinib), in the indication against an advanced form of non-small cell lung cancer.
The multinational pharmaceutical company details in its press release on Wednesday the phase II Geometry mono-1 study on which the approval is based. This showed an overall response rate (ORR) of 51.6% in all 100 second-line patients and 44% in all patients previously treated for advanced non-small cell lung cancer (NSCLC). ) with alterations leading to the skipping of exon 14 of MET1.
The approval follows a positive opinion issued in April by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
ib/jh